AstraZeneca vaccine: what we know about rare atypical thromboses
FOCUS – The identification of these cases in greater numbers than expected in people vaccinated with AstraZeneca raises many questions. Le Figaro takes stock.
What are we talking about?
While the involvement of the AstraZeneca vaccine in the occurrence of “classic” thromboses (phlebitis, pulmonary embolism) has been definitively ruled out, its role in atypical thrombosis is highly suspected. We are talking about rare forms of blood clot occurring in the brain (cerebral venous sinus thrombosis) or in one of the large veins of the abdomen, often associated with thrombocytopenia, that is to say a decrease in platelets, cells that participate in coagulation. For now, the EMA has recognized a “Possible link” with the vaccine, without being certain.
How many cases have been reported?
As of April 4, 169 cases of cerebral venous sinus thrombosis and 53 cases of splanchnic venous thrombosis (in the viscera) were registered in EudraVigilance – the database for monitoring adverse drug reactions in the European Union and the United Kingdom – , out of a total of about 34 million people vaccinated. That is to say a very low frequency of 6.5 cases per million people vaccinated.
This article is for subscribers only. You have 79% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in